Hotsia.Com : เที่ยวสะใจ

The Chronic Kidney Disease Solution™ By Shelly Manning It is an eBook that includes the most popular methods to care and manage kidney diseases by following the information provided in it. This easily readable eBook covers up various important topics like what is chronic kidney disease, how it is caused, how it can be diagnosed, tissue damages caused by chronic inflammation, how your condition is affected by gut biome, choices for powerful lifestyle and chronic kidney disease with natural tools etc.

---

CKD and diabetic nephropathy

Chronic Kidney Disease (CKD) and diabetic nephropathy (DN) are closely intertwined, with diabetic nephropathy being the leading cause of CKD worldwide. Diabetic nephropathy refers to the kidney damage that occurs due to long-standing diabetes, both type 1 and type 2, and is a major microvascular complication of diabetes. It is characterized by persistent proteinuria, declining kidney function, and an increased risk of cardiovascular disease (CVD). Diabetic nephropathy is a progressive condition that can lead to end-stage renal disease (ESRD), requiring dialysis or kidney transplantation.

Epidemiology

• Diabetic nephropathy affects approximately 20-40% of people with diabetes.
• It is the most common cause of ESRD in developed countries, accounting for around 40% of all cases.
• The incidence of diabetic nephropathy is increasing globally due to the rising prevalence of diabetes, particularly type 2 diabetes, driven by obesity, sedentary lifestyles, and aging populations.

Pathophysiology of Diabetic Nephropathy

The development of diabetic nephropathy is driven by a combination of metabolic and hemodynamic changes associated with diabetes. Hyperglycemia plays a central role in initiating kidney damage, while other factors such as hypertension, inflammation, and genetic predisposition contribute to the progression of nephropathy.

1. Hyperglycemia: Chronic hyperglycemia is the primary trigger for the development of diabetic nephropathy. It leads to the production of advanced glycation end products (AGEs), which cause oxidative stress and inflammation. AGEs interact with their receptors (RAGEs) on various cells, inducing the release of pro-inflammatory cytokines and growth factors that contribute to kidney damage.
2. Glomerular Hyperfiltration: In the early stages of diabetic nephropathy, hyperglycemia leads to increased glomerular filtration rate (GFR), a phenomenon known as glomerular hyperfiltration. This is driven by an imbalance in afferent and efferent arteriolar tone, causing increased intraglomerular pressure. Over time, the excessive strain on the glomeruli causes damage to the capillaries, leading to the development of proteinuria.
3. Podocyte Injury: Podocytes are specialized cells that play a crucial role in maintaining the integrity of the glomerular filtration barrier. In diabetic nephropathy, hyperglycemia and the accumulation of AGEs lead to podocyte injury and apoptosis. Podocyte loss disrupts the filtration barrier, allowing proteins such as albumin to leak into the urine, leading to proteinuria.
4. Basement Membrane Thickening: Hyperglycemia induces thickening of the glomerular basement membrane (GBM) due to the accumulation of extracellular matrix (ECM) proteins such as collagen. This thickening impairs the ability of the glomerulus to filter blood properly and contributes to the development of glomerulosclerosis, a hallmark of diabetic nephropathy.
5. Mesangial Expansion: Mesangial cells, located in the central part of the glomerulus, are responsible for maintaining the structure of the glomerular tuft. In diabetic nephropathy, mesangial cells undergo hypertrophy and proliferation due to the effects of hyperglycemia, leading to mesangial expansion. The excessive deposition of ECM in the mesangium contributes to glomerulosclerosis and loss of kidney function.
6. Inflammation and Fibrosis: Inflammation plays a critical role in the progression of diabetic nephropathy. Hyperglycemia and AGEs trigger the release of pro-inflammatory cytokines (e.g., interleukin-6, TNF-α) and chemokines that recruit immune cells to the kidney. This inflammatory response exacerbates kidney injury and promotes fibrosis. Transforming growth factor-beta (TGF-β), a key mediator of fibrosis, is upregulated in diabetic nephropathy, leading to the accumulation of ECM proteins and the development of tubulointerstitial fibrosis.
7. Hypertension: Hypertension is both a cause and consequence of diabetic nephropathy. High blood pressure increases intraglomerular pressure, accelerating kidney damage. Conversely, kidney dysfunction impairs the regulation of blood pressure, further exacerbating hypertension. The interplay between hypertension and diabetic nephropathy creates a vicious cycle that accelerates the progression to ESRD.

Stages of Diabetic Nephropathy

Diabetic nephropathy progresses through several stages, each characterized by specific clinical and histological changes:

1. Hyperfiltration (Stage 1): This early stage is marked by an increase in GFR due to glomerular hyperfiltration. Patients are usually asymptomatic, and there are no detectable abnormalities in kidney function tests or urinalysis.
2. Microalbuminuria (Stage 2): As kidney damage progresses, small amounts of albumin begin to leak into the urine (microalbuminuria), defined as 30-300 mg of albumin per day. This stage is often reversible with appropriate glycemic and blood pressure control.
3. Overt Proteinuria (Stage 3): In this stage, the amount of protein in the urine increases significantly (macroalbuminuria), with more than 300 mg of albumin excreted per day. Proteinuria is a key marker of glomerular damage and predicts the progression to ESRD. Patients may begin to experience symptoms such as edema and fatigue.
4. Declining GFR (Stage 4): As the disease progresses, GFR declines, reflecting worsening kidney function. Patients may develop symptoms of CKD, including fatigue, nausea, loss of appetite, and fluid retention. At this stage, there is an increased risk of cardiovascular events.
5. End-Stage Renal Disease (Stage 5): In the final stage, GFR falls below 15 mL/min/1.73 m², indicating ESRD. Patients require renal replacement therapy, such as dialysis or kidney transplantation, to survive. Cardiovascular disease is the leading cause of death in patients with ESRD due to diabetic nephropathy.

Clinical Manifestations of Diabetic Nephropathy

1. Proteinuria: Persistent proteinuria is the hallmark of diabetic nephropathy. In the early stages, microalbuminuria may be the only detectable abnormality. As the disease progresses, macroalbuminuria develops, leading to significant protein loss in the urine. Proteinuria is a predictor of cardiovascular events and disease progression in diabetic nephropathy.
2. Hypertension: Hypertension is a common complication of diabetic nephropathy and often worsens as kidney function declines. It is both a cause and consequence of kidney damage and must be aggressively managed to slow the progression of nephropathy.
3. Edema: Patients with diabetic nephropathy may develop edema, particularly in the legs and around the eyes, due to the loss of proteins such as albumin in the urine, which reduces the oncotic pressure in the blood vessels.
4. Cardiovascular Disease: Diabetic nephropathy significantly increases the risk of cardiovascular events such as myocardial infarction, stroke, and heart failure. The presence of proteinuria and reduced GFR are independent risk factors for cardiovascular disease in diabetic patients.
5. Symptoms of CKD: As kidney function declines, patients may develop symptoms of CKD, including fatigue, nausea, loss of appetite, weight loss, and fluid retention. In advanced stages, patients may also experience uremic symptoms such as itching, confusion, and muscle cramps.

Diagnosis of Diabetic Nephropathy

Early diagnosis of diabetic nephropathy is critical to slowing disease progression and preventing ESRD. Diagnosis is based on the detection of proteinuria, assessment of kidney function, and evaluation of risk factors such as hypertension and hyperglycemia.

1. Urine Albumin Excretion:
   • Microalbuminuria: The first sign of diabetic nephropathy is the presence of microalbuminuria, which is detected using a urine albumin-to-creatinine ratio (UACR) test. A UACR of 30-300 mg/g indicates microalbuminuria.
   • Macroalbuminuria: Persistent macroalbuminuria (UACR > 300 mg/g) is diagnostic of overt nephropathy and indicates significant glomerular damage.
2. Glomerular Filtration Rate (GFR): GFR is estimated using serum creatinine levels and equations such as the CKD-EPI formula. A declining GFR indicates worsening kidney function and is used to stage CKD in diabetic nephropathy patients.
3. Blood Pressure Monitoring: Hypertension is a major risk factor for diabetic nephropathy progression. Blood pressure should be regularly monitored and aggressively controlled in diabetic patients.
4. Kidney Biopsy: In some cases, a kidney biopsy may be performed to confirm the diagnosis of diabetic nephropathy and assess the extent of glomerular and tubulointerstitial damage. However, biopsy is not routinely performed unless the clinical picture is atypical or another kidney disease is suspected.
5. Other Tests: Blood tests to assess glycemic control (e.g., HbA1c), lipid profiles, and markers of inflammation (e.g., CRP) can help guide management and assess the risk of complications.

Management of Diabetic Nephropathy

The management of diabetic nephropathy focuses on controlling blood glucose levels, reducing blood pressure, managing proteinuria, and preventing cardiovascular complications. Early intervention is essential to slow the progression of kidney disease and reduce the risk of ESRD.

1. Glycemic Control

• Tight Glycemic Control: Maintaining optimal blood glucose levels is critical in preventing the onset and progression of diabetic nephropathy. A target HbA1c of <7% is generally recommended, though individualized targets may be necessary to avoid hypoglycemia in patients with advanced CKD.
• SGLT2 Inhibitors: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin and canagliflozin, have emerged as key agents in the management of diabetic nephropathy. These drugs reduce blood glucose levels, decrease intraglomerular pressure, and slow the progression of kidney disease. They have also been shown to reduce the risk of cardiovascular events in diabetic patients.
• GLP-1 Receptor Agonists: Glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide, have demonstrated renoprotective effects and reduce cardiovascular risk in diabetic patients. They are particularly useful in patients with both diabetes and CKD.

2. Blood Pressure Control

• ACE Inhibitors and ARBs: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are the first-line agents for managing hypertension in diabetic nephropathy. These medications reduce intraglomerular pressure, decrease proteinuria, and slow the progression of kidney disease. A target blood pressure of <130/80 mmHg is recommended in most patients with diabetic nephropathy.
• Calcium Channel Blockers and Diuretics: In patients who do not achieve blood pressure control with ACE inhibitors or ARBs, calcium channel blockers or diuretics may be added to the treatment regimen.

3. Proteinuria Reduction

• ACE Inhibitors and ARBs: In addition to controlling blood pressure, ACE inhibitors and ARBs have direct effects on reducing proteinuria. Reducing proteinuria is critical for slowing the progression of diabetic nephropathy and preserving kidney function.

4. Lipid Management

• Statins: Dyslipidemia is common in diabetic nephropathy and contributes to cardiovascular disease risk. Statins are recommended for all patients with diabetic nephropathy to lower LDL cholesterol levels and reduce the risk of cardiovascular events.

5. Cardiovascular Risk Reduction

• Antiplatelet Therapy: Low-dose aspirin may be considered for patients with diabetic nephropathy who are at high risk for cardiovascular events.
• Lifestyle Modifications: Smoking cessation, weight loss, and increased physical activity are important lifestyle interventions to reduce cardiovascular risk and slow the progression of kidney disease.

6. Renal Replacement Therapy

• Dialysis: In patients who progress to ESRD, dialysis (hemodialysis or peritoneal dialysis) is required to replace kidney function. Early referral to a nephrologist is critical for planning renal replacement therapy.
• Kidney Transplantation: Kidney transplantation is the preferred treatment for ESRD in diabetic nephropathy, as it offers the best long-term survival and quality of life.

Prognosis of Diabetic Nephropathy

The prognosis of diabetic nephropathy depends on early detection, effective management, and the presence of comorbid conditions. With optimal treatment, the progression of diabetic nephropathy can be slowed, and the risk of ESRD can be reduced. However, patients with diabetic nephropathy remain at high risk for cardiovascular events, and cardiovascular disease is the leading cause of death in these patients.

Conclusion

Diabetic nephropathy is a serious and prevalent complication of diabetes that significantly contributes to the global burden of CKD and ESRD. Early detection and aggressive management of hyperglycemia, hypertension, and proteinuria are critical to slowing the progression of diabetic nephropathy and reducing the risk of kidney failure and cardiovascular events. Advances in pharmacological therapies, such as SGLT2 inhibitors and GLP-1 receptor agonists, offer new hope for patients with diabetic nephropathy by providing renoprotective and cardioprotective benefits. A multidisciplinary approach involving nephrologists, endocrinologists, and primary care providers is essential for the optimal management of diabetic nephropathy and improving patient outcomes.

The Chronic Kidney Disease Solution™ By Shelly Manning It is an eBook that includes the most popular methods to care and manage kidney diseases by following the information provided in it. This easily readable eBook covers up various important topics like what is chronic kidney disease, how it is caused, how it can be diagnosed, tissue damages caused by chronic inflammation, how your condition is affected by gut biome, choices for powerful lifestyle and chronic kidney disease with natural tools etc.

I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. I share my experiences on www.hotsia.com